fluoxetine / Generic mfg. - LARVOL DELTA

PARACHUTES: Pedophilia At Risk Acute Treatment E-therapy vs SSRI (clinicaltrialsregister.eu) - P1/2 | N=111 | Recruiting | Sponsor: Karolinska University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

Exploring Molecular Mechanism of Fluoxetine in Animal Models of Depression via Integrated Metabolomic and Proteomic Analysis. (PubMed, J Cell Mol Med) - "Drug-associated metabolite set enrichment analysis revealed 76 significantly enriched drug-related pathways, which were mainly involved in antidepressants. This study provides a comprehensive understanding of the antidepressant effects of fluoxetine, which may provide insights for the development of novel antidepressants."

Journal • Preclinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

Development of a baseline battery to optimize depression treatment assignment in primary care: Balancing breadth and brevity. (PubMed, J Affect Disord) - "This study shows how a structured, data-driven development process can yield a scientifically robust baseline assessment battery capturing a broad range of candidate treatment moderators. The battery will undergo further refinement following the results of the OptimizeD trial, which will identify the subset of baseline characteristics that meaningfully predict differential treatment response. While not intended as an implementation-ready clinical tool, the development framework presented here may help guide other researchers conducting similar precision treatment studies, particularly in resource-constrained settings."

Journal • CNS Disorders • Depression • Fatigue • Mood Disorders • Psychiatry

Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis. (PubMed, Sex Med) - "Comparative analysis of antidepressant-related adverse events in the FAERS database showed that while sexual dysfunction was associated with all studied SSRIs/SNRIs (sertraline, citalopram/escitalopram, paroxetine, fluoxetine, venlafaxine, and duloxetine), symptom profiles varied markedly. But the limitation is FAERS' passive surveillance nature, which may involve underreporting or insufficient clinical context, restricting causal inference. While previous studies have not fully elucidated antidepressant-related sexual dysfunction, our findings delineate distinct sexual adverse effect profiles between SSRIs and SNRIs, contributing valuable evidence for personalized treatment approaches."

Adverse events • Journal • Sexual Disorders

An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications. (PubMed, Expert Opin Drug Metab Toxicol) - "Some antidepressants, including fluoxetine, paroxetine, fluvoxamine, are moderate to strong inhibitors of various cytochrome P450 (CYP) isoenzymes and may cause clinically relevant interactions with ASMs metabolized by these pathways. First-generation ASMs with enzyme-inducing properties (e.g. carbamazepine, phenobarbital, and phenytoin) or enzyme-inhibiting effects (e.g. valproic acid) may alter the PK profile of several antidepressants, potentially leading to reduced therapeutic efficacy or dose-dependent toxicity...Antidepressants and ASMs are associated with a considerable risk of clinically significant DDIs. A thorough understanding of the underlying PK and PD mechanisms, combined with complementary strategies including therapeutic drug monitoring, consultation of interaction databases, and careful clinical monitoring, is essential to anticipate, prevent, and effectively manage adverse DDIs."

Journal • PK/PD data • Review • CNS Disorders • Epilepsy

FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner. (PubMed, bioRxiv) - "Various classes of drugs, such as antidepressants (Fluoxetine, Duloxetine), antihypertensives (Irbesartan, amlodipine, nebivolol), antidiabetics (Rosiglitazone), β-adrenergic agonists (Salmeterol), antimalarials (Mefloquine), antifungals (Azoles, ciclopirox), and antivirals (Saquinavir, Remdesivir), were identified as potent blockers of either priming or assembly of NLRP3 inflammasome. Mice treated with LPS-priming blockers showed a sex-specific increase in survival rate in the mouse model of LPS-induced mortality, validating the in vitro screen. Further studies in primary human cells and in vivo disease models are needed to assess the repurposing and therapeutic relevance of identified drugs."

FDA event • Journal • Alzheimer's Disease • Asthma • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Genetic Disorders • Gout • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Movement Disorders • Novel Coronavirus Disease • Obesity • Parkinson's Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • NLRP3

Anxiolytic and Antidepressant-Like Effects of a Probiotic Mixture HMLH123 Potentially via the Serotonergic Pathway in Wistar Rats. (PubMed, Behav Neurol) - "While no synergistic interaction with fluoxetine was observed, treatment with the probiotic mixture showed positive effects independently. Further research should explore its mechanisms of action and therapeutic applications as a standalone intervention."

Journal • Preclinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • CNS Disorders • Depression • Gallbladder Cancer • Hepatocellular Cancer • Mood Disorders • Oncology • Psychiatry

Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials. (PubMed, ACS Pharmacol Transl Sci) - "Together, these findings demonstrate that SSRI treatment history can alter the behavioral efficacy of psychedelics in a way that may be compound specific. These results have important implications for psychedelic-assisted therapies in populations taking SSRIs and highlight the need for translational studies to inform cotreatment strategies and guide clinical trial design."

Journal • Preclinical • CNS Disorders • Mood Disorders • Psychiatry

Loneliness, serotonin, and medial prefrontal cortex: some empirical and theoretical considerations. (PubMed, Pharmacol Biochem Behav) - No abstract available

Journal

Predicting the potential for organic cation transporter 1-mediated drug-drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil. (PubMed, Expert Opin Drug Metab Toxicol) - "An in vitro OCT1 inhibition assay using fenoterol as probe substrate was validated and identified that verapamil may pose a clinically relevant interaction risk, predicting a minimum 2-fold increase in fenoterol exposure. This highlights the need for caution when coadministrating verapamil with fenoterol and supports incorporating OCT1 inhibition profiling into preclinical evaluation of new drug entities to better inform clinical development and ensure patient safety."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • SLC22A1

TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (clinicaltrials.gov) - P4 | N=180 | Recruiting | Sponsor: Poznan University of Medical Sciences

New P4 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Nausea and dystonia in a woman with psychiatric illness (PubMed, Ugeskr Laeger) - "Fluoxetine, a potent CYP2D6 inhibitor, may have increased exposure to metoclopramide and promethazine. This case report demonstrates that pharmacological insight and deprescribing can improve symptoms and support rational pharmacotherapy in vulnerable psychiatric patients."

Journal • CNS Disorders • Dystonia • Mental Retardation • Movement Disorders • Psychiatry

Effect of Tongdu Tiaoshen acupuncture on hippocampal neuronal synaptic remodeling in rats with post-stroke depression based on the CCL2-CCR2 pathway (PubMed, Zhongguo Zhen Jiu) - "Forty-eight successfully modeled rats were randomly divided into a model group, an acupuncture group, a fluoxetine group, and an acupuncture+agonist group, with 12 rats in each group...Compared with the acupuncture+agonist group, the acupuncture group showed better improvement in all indexes (P<0.05). Tongdu Tiaoshen acupuncture could improve neurological function and depressive-like behavior in PSD rats, possibly by inhibiting the CCL2-CCR2 pathway and promoting neuronal synaptic remodeling in the hippocampus."

Journal • Preclinical • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Oncology • Psychiatry • CCL2 • CCR2 • DLG4 • IL10 • IL6 • Napsin A • SYP • TNFA

MAMMA MIA! THE EFFECT OF PERINATAL MATERNAL FACTORS IN THE NEONATAL QT (ACC 2026) - "Maternal exposure to oxytocin (p < 0.01), butorphanol (p = 0.03), norethisterone (p = 0.04), and fluoxetine (p = 0.04) were associated with significantly prolonged QTc interval, while magnesium was associated with shortened QTc (p = 0.02). QTc prolongation in neonates is common. Perinatal medications, epidural anesthesia, gestational age, postnatal age and ethnicity can affect QTc. When QTc prolongation is noted in a neonate, associated maternal perinatal exposures should be explored."

Cardiovascular • Heart Failure

Impact of fluoxetine on innate immunity and melanoma metastasis in mice. (PubMed, Adv Med Sci) - "Obtained data confirm the inhibitory effect of fluoxetine on melanoma growth, but only when this antidepressant is given to animals that already struggle with melanoma development. Fluoxetine administration before cancer development accelerates its progress and induces unbeneficial changes in immunity and metalloproteinase levels in comparison to saline-pretreated mice."

Journal • Preclinical • CNS Disorders • Depression • Melanoma • Oncology • Psychiatry • Solid Tumor • MMP9

Interaction of Fluoxetine and Caffeine in a Patient With Substance-Induced Mania. (PubMed, Bipolar Disord) - "This case highlights a possible interaction between fluoxetine and caffeine contributing to mania and underscores the importance of assessing stimulant use and medication dosing when evaluating new-onset manic symptoms."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration. (PubMed, Expert Opin Drug Discov) - "Notably, anti-diabetic agents including metformin, sulfonylureas, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and insulin have emerged as modulators of the retinal pigment epithelium (RPE) function, photoreceptors, and retinal vascular integrity...Additional pharmacological agents include statins, glyburide, L-DOPA, fluoxetine, dimethyl fumarate, and nutraceuticals such as curcumin, melatonin, and N-acetylcysteine. Early AMD prevention through repurposed therapeutics, guided by AI-driven design and systems biology, may enable personalized care via multimodal risk stratification incorporating genetic, metabolomic, and microbiome data. Rigorous, stratified clinical trials integrating bioinformatics and precision medicine are essential to validate the most effective candidates."

Journal • Review • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders

Case Report: Four cases for cariprazine and alcohol use disorder. (PubMed, Front Psychiatry) - "All four patients were treated during the years with many different pharmacologic protocols, involving antipsychotics (olanzapine, quetiapine), mood stabilizers (carbamazepine, lamotrigine), anxiolytics (clonazepam, bromazepam), SSRI antidepressants (fluoxetine, paroxetine, escitalopram), but without achieving of the alcohol abstinence. The consistent achievement of full abstinence across all four patients suggests that it may have potential relevance in the management of alcohol use disorder (AUD). However, in the future, well conducted and highly controlled studies are needed to explore a potential cariprazine's role and its place in the management of alcohol dependence."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders

Antifungal effects of paroxetine and fluoxetine, synergism with antifungal drugs, and mode of action against Candida spp. (PubMed, Mycologia) - "The minimum inhibitory concentrations (MICs) were determined for PRX, FLX, and for the antifungals fluconazole, itraconazole, and amphotericin B (AMB), and checkerboard assay was performed to analyze the interactions between them. Additionally, their mechanisms of action can be related to the induction of severe oxidative stress that leads to apoptosis in fungal cells showing a synergistic effect when combined with AMB. Thus, the use of PRX and FLX may be an alternative to treat infections caused by resistant microorganisms, by enhanced effects at lower concentrations when combined with AMB, possibly reducing the risk of toxicity of both drugs."

Journal • Infectious Disease

Accumulation and Metabolism of Wastewater-Derived Psychoactive Pharmaceuticals in Edible Crop Plants. (PubMed, Environ Sci Technol) - "To address this knowledge gap, semihydroponically grown lettuce, tomatoes, and carrots were exposed to four psychoactive pharmaceuticals─carbamazepine (CBZ), lamotrigine (LTG), amitriptyline (AMI), and fluoxetine (FLX)─for 28, 45, and 15 days, respectively. Liquid chromatography-high-resolution mass spectrometry analysis revealed 15, 7, 38, and 27 metabolites of CBZ, LTG, AMI, and FLX, respectively, including 15 novel in planta metabolites, among which were N-acylation products of the amine-containing LTG, AMI, and FLX. Similar metabolic pathways were observed across the three plant types, with the detection of more complex metabolites tied to higher tissue concentrations of parent compounds rather than to species specificity."

Journal

Integrating Neurotrophic and Anti-inflammatory Pathways: Press-needle Acupuncture as a Multi-target Therapy for Adolescent Depression. (PubMed, Int J Neurosci) - "Male rats were randomly allocated into four groups (n = 8): Normal control group (CON), Chronic Unpredictable Mild Stress(CUMS) group (CUMS), Press-needle group (PN), and Fluoxetine group (FLX)...Notably, press-needle exerted anti-neuroinflammatory effects, reducing hippocampal and serum levels of TNF-α and IL-6. Histopathological analysis confirmed its neuroprotective efficacy, demonstrating attenuated neuronal damage in hippocampal tissues."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry • IL6 • TNFA

Prediction of Large-Scale Adsorption Process Parameters Using Two-Mechanism Langmuir Constants. (PubMed, Pharm Res) - "The adsorption of barbituric acid, fluoxetine, phenobarbital, and procaine to 4 types of commercial activated carbons at different pH values, temperatures, buffers, and cosolvents is studied as an example. For adsorbates with a high extent of hydrophobic bonding, great reductions in concentrations, approaching zero, can be achieved even at high initial concentrations. The derived equation is free of assumptions, and is not specific to the systems studied."

Journal

Hippocampal GPR17 is involved in chronic restraint stress-induced depressive-like behaviors by regulating neuroinflammation and glutamatergic activity in mice. (PubMed, Int Immunopharmacol) - "Moreover, molecular docking revealed that fluoxetine binds to GPR17. We also found that hippocampal glutamatergic neuronal activity is required for antidepressant-like effects of GPR17 antagonist cangrelor. These results suggest that GPR17 regulates chronic stress-induced depressive-like behaviors and hippocampal synaptic transmission through the TLR4/NF-κB/NLRP3 signaling pathway, establishing it as a promising novel therapeutic target for depression."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Psychiatry • NLRP3 • TLR4

Clinical Evaluation of Drug-Drug Interactions With Aficamten. (PubMed, Clin Transl Sci) - "Aficamten as a victim of DDIs was studied using a moderate-to-strong P450 inducer (carbamazepine) and CYP inhibitors-itraconazole (strong CYP3A), paroxetine (strong CYP2D6), fluconazole (strong CYP2C19 and moderate 2C9 and 3A), and fluoxetine (strong CYP2D6 and 2C19). Aficamten's potential for P-glycoprotein (P-gp) inhibition was assessed using dabigatran etexilate (sensitive P-gp substrate)...In conclusion, aficamten is metabolized by multiple P450 enzymes, limiting its DDI liability. Only weak DDIs (< 2-fold) are likely from strong inhibition of any one pathway, and only moderate (< 5-fold) impact on aficamten exposure is expected with strong multi-pathway inhibitors or inducers."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • CYP2C19 • CYP2C9